Changes in Drug Survival of Adalimumab Over Time in Patients with Psoriasis – A Nationwide Cohort Study

This study found that the increased number of available biologic therapies did not have a negative impact on the drug survival of adalimumab. On the contrary, discontinuation risk was significantly lower in 2019-2024 compared with 2007-2016. The concurrent introduction of lower-cost biosimilars and the associated rise in dose escalation may have contributed to the improved drug survival observed in the later period.